Tadeusz Hawrot met with Hugh Laverty, Head of Scientific Operations and Elisabetta Vaudano, Principal Scientific Manager & Responsible Strategic Area Neuroscience. In this meeting they discussed methods to translate health research and innovation into tangible benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research.

PAREA’s proposal to have an EU mental health strategy was acknowledged alongside ideas from other stakeholders. These suggestions were made into a poster format and shared with several hundreds of participants at a recent online EU4Health meeting. The Commission will also share all the posters with the relevant EU member states’ health authorities.

New EU partnership PAREA sets to pave the way for psychedelic-assisted therapies to help patients in areas of huge unmet needs says Tadeusz Hawrot, founder and policy lead at PAREA.

PAREA members launched a Call to Action to European decision makers-bringing together our key priorities and policy asks.

EU4Health is seeking the opinions of stakeholders about current and future EU health priorities, strategic orientations and key health needs to be addressed through EU4Health annual Work Programmes.

PAREA recently submitted a contribution to this consultation arguing that psychedelic-assisted psychotherapy ought to be a key priority for EU healthcare over the next few years.

“The Psychedelic Access and Research European Alliance (PAREA) is aiming to advance the dialogue around the implementation of psychedelic healthcare in Europe.” - Psychedelic Health

For the first time, in known history, EU policy recommendations were made featuring psychedelic-assisted psychotherapy.

”New models of innovative/unusual treatments when they target unmet needs or vulnerable situations, for instance, psychedelic assisted therapies for brain disorders, which constitute a paradigm shift in the pharmacological space because these therapies will need to be registered as both a medicinal product and therapy.”

PAREA provided recommendations on future areas for excellent, innovative and translational brain research in Europe. Shared European Brain Research Agenda covers all brain research fields and brain disorders, including both psychiatric and neurological disorders and will serve as a framework to guide future brain research investments in Europe.

PAREA calls on the EU to embark on more research activity and to stimulate innovation with regard to the use of psychedelics for medicinal purposes.

The European Commission is working on a new ‘Healthier Together’ – EU Non-communicable diseases initiative to support EU countries in reducing the burden of NCDs, focusing on 5 key areas, including mental and neurological disorders. PAREA contributed to this initiative by making a detailed submission as part of the stakeholder consultations

A part of the bi-monthly investor series, this virtual Microdose Conference explores the new technologies driving the industry, the scope of psychedelic investments and the prospects. It offers a forum to connect businesses to the top capitalists and investors of the psychedelic spectrum. These online sessions offer tremendous networking scope where businesses build strong ties and associations.